RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $300 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated an Outperform rating for Alnylam Pharmaceuticals, maintaining a price target of $300.
November 01, 2024 | 4:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reiterated its Outperform rating for Alnylam Pharmaceuticals, maintaining a price target of $300, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and a maintained price target of $300 by RBC Capital suggests a positive outlook for Alnylam Pharmaceuticals. This could lead to increased investor confidence and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100